Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity

Infection and Immunity

Volumn 83, Issue 4, 2015, Pages 1536-1545

  Giuntini, Serena ^a   Pajon, Rolando ^a   Ram, Sanjay ^b   Granoff, Dan M ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR H; MENINGOCOCCUS VACCINE; RECOMBINANT FACTOR H BINDING PROTEIN 1 VACCINE; RECOMBINANT FACTOR H BINDING PROTEIN 4 VACCINE; RECOMBINANT FACTOR H BINDING PROTEIN 55 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; FACTOR H-BINDING PROTEIN, NEISSERIA MENINGITIDIS; MONOCLONAL ANTIBODY; NSPA PROTEIN, NEISSERIA; OUTER MEMBRANE PROTEIN; PORIN; PORIN PROTEIN, NEISSERIA; PROTEIN BINDING;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIOLYSIS; BACTERIUM ISOLATE; BACTERIUM MUTANT; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; DOWN REGULATION; DRUG PROTEIN BINDING; GENE EXPRESSION; GENE INACTIVATION; IMMUNE EVASION; INFANT; MOUSE; NEISSERIA MENINGITIDIS; NEISSERIAL SURFACE PROTEIN A GENE; NONHUMAN; PORB3 GENE; PRIORITY JOURNAL; RAT; SEROTYPE; SERUM BACTERICIDAL ACTIVITY; WILD TYPE RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DNA SEQUENCE; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGITIS, MENINGOCOCCAL; MUTATION; NUCLEOTIDE SEQUENCE; WISTAR RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BASE SEQUENCE; COMPLEMENT FACTOR H; GENE KNOCKOUT TECHNIQUES; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MUTATION; NEISSERIA MENINGITIDIS, SEROGROUP B; PORINS; PROTEIN BINDING; RATS; RATS, WISTAR; SEQUENCE ANALYSIS, DNA;

EID: 84925356212     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02984-14     Document Type: Article

References (46)

1. McNeil LK, Zagursky RJ, Lin SL, Murphy E, Zlotnick GW, Hoiseth SK, Jansen KU, Anderson AS. 2013. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev 77:234-252. http://dx.doi.org/10.1128/MMBR.00056-12.
2. Serruto D, Bottomley MJ, Ram S, Giuliani MM, Rappuoli R. 2012. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional, and structural characterization of the antigens. Vaccine 30(Suppl 2):B87-B97. http://dx.doi.org/10.1016/j.vaccine.2012.01.033.
3. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M, Xie X, Zagursky R, Zhang Y, Zlotnick GW. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72:2088-2100. http://dx.doi.org/10.1128/IAI.72.4.2088-2100.2004.
4. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, Ambrose K, Borrow R, Findlow J, Taha MK, Deghmane AE, Kriz P, Musilek M, Kalmusova J, Caugant DA, Alvestad T, Mayer LW, Sacchi CT, Wang X, Martin D, von Gottberg A, du Plessis M, Klugman KP, Anderson AS, Jansen KU, Zlotnick GW, Hoiseth SK. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200:379-389. http://dx.doi.org/10.1086/600141.
5. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, Brunelli B, Pieri A, Santini L, Savino S, Serruto D, Litt D, Kroll S, Welsch JA, Granoff DM, Rappuoli R, Pizza M. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197:789-799. http://dx.doi.org/10.1084/jem.20021911.
6. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, Muzzi A, Andrews W, Chen J, Santos G, Santini L, Boucher P, Serruto D, Pizza M, Rappuoli R, Giuliani MM. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of proteinbased vaccines. Proc Natl Acad Sci U S A 107:19490-19495. http://dx.doi.org/10.1073/pnas.1013758107.
7. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, Scott AA, Alexander K, Mason K, Miller L, DaSilva I, Mack M, Zhao XJ, Pride MW, Andrew L, Murphy E, Hagen M, French R, Arora A, Jones TR, Jansen KU, Zlotnick GW, Anderson AS. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086-6093. http://dx.doi.org/10.1016/j.vaccine.2010.06.083.
8. McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris S, Scott A, Tan C, Mack M, Dasilva I, Alexander K, Jiang HQ, Zhu D, Mininni T, Zlotnick GW, Hoiseth SK, Jones TR, Pride M, Jansen KU, Anderson A. 2009. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27:3417-3421. http://dx.doi.org/10.1016/j.vaccine.2009.01.075.
9. Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, Medini D. 2013. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 31:4968-4974. http://dx.doi.org/10.1016/j.vaccine.2013.08.006.
10. Vogel U, Stefanelli P, Vazquez J, Taha MK, Claus H, Donnelly J. 2012. The use of vaccine antigen characterization, for example, by MATS, to guide the introduction of meningococcus B vaccines. Vaccine 30(Suppl 2):B73-B77. http://dx.doi.org/10.1016/j.vaccine.2011.12.061.
11. Vogel U, Taha MK, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, Carannante A, Deghmane AE, Fazio C, Frosch M, Frosi G, Gilchrist S, Giuliani MM, Hong E, Ledroit M, Lovaglio PG, Lucidarme J, Musilek M, Muzzi A, Oksnes J, Rigat F, Orlandi L, Stella M, Thompson D, Pizza M, Rappuoli R, Serruto D, Comanducci M, Boccadifuoco G, Donnelly JJ, Medini D, Borrow R. 2013. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis 13:416-425. http://dx.doi.org/10.1016/S1473-3099(13)70006-9.
12. Beernink PT, Welsch JA, Harrison LH, Leipus A, Kaplan SL, Granoff DM. 2007. Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 195:1472-1479. http://dx.doi.org/10.1086/514821.
13. Holst J, Comanducci M, Bambini S, Muzzi A, Comandi S, Oksnes J, DeTora L, Pizza M, Rappuoli R, Caugant DA. 2014. Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway. Vaccine 32:2722-2731. http://dx.doi.org/10.1016/j.vaccine.2014.02.068.
14. Kaplan SL, Schutze GE, Leake JA, Barson WJ, Halasa NB, Byington CL, Woods CR, Tan TQ, Hoffman JA, Wald ER, Edwards KM, Mason EO, Jr. 2006. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics 118:e979-984. http://dx.doi.org/10.1542/peds.2006-0281.
15. Mandrell RE, Kim JJ, John CM, Gibson BW, Sugai JV, Apicella MA, Griffiss JM, Yamasaki R. 1991. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol 173:2823-2832.
16. Giuntini S, Vu DM, Granoff DM. 2013. fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. Vaccine 31:4192-4199. http://dx.doi.org/10.1016/j.vaccine.2013.06.009.
17. Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U, Ram S. 2010. The meningococcal vaccine candidate neisserial surface proteinA(NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog 6:e1001027. http://dx.doi.org/10.1371/journal.ppat.1001027.
18. Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. 2002. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70:6021-6031. http://dx.doi.org/10.1128/IAI.70.11.6021-6031.2002.
19. Abad R, Alcala B, Salcedo C, Enriquez R, Uria MJ, Diez P, Vazquez JA. 2006. Sequencing of the porB gene: a step toward a true characterization of Neisseria meningitidis. Clin Vaccine Immunol 13:1087-1091. http://dx.doi.org/10.1128/CVI.00211-06.
20. Sacchi CT, Lemos AP, Whitney AM, Solari CA, Brandt ME, Melles CE, Frasch CE, Mayer LW. 1998. Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system. Clin Diagn Lab Immunol 5:348-354.
21. Koeberling O, Welsch JA, Granoff DM. 2007. Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. Vaccine 25:1912-1920. http://dx.doi.org/10.1016/j.vaccine.2006.03.092.
22. Lewis LA, Carter M, Ram S. 2012. The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol 188:5063-5072. http://dx.doi.org/10.4049/jimmunol.1103748.
23. Apicella MA, Bennett KM, Hermerath CA, Roberts DE. 1981. Monoclonal antibody analysis of lipopolysaccharide from Neisseria gonorrhoeae and Neisseria meningitidis. Infect Immun 34:751-756.
24. Apicella MA. 2008. Isolation and characterization of lipopolysaccharides, p 1-11. In DeLeo FR, Otto M (ed), Bacterial pathogenesis: methods and protocols, vol 431. Humana Press, Totowa, NJ.
25. Konar M, Granoff DM, Beernink PT. 2013. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis 208:627-636. http://dx.doi.org/10.1093/infdis/jit239.
26. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol 186:3606-3614. http://dx.doi.org/10.4049/jimmunol.1003470.
27. Giuntini S, Reason DC, Granoff DM. 2011. Complement-mediated bactericidal activity of anti-factorHbinding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun 79:3751-3759. http://dx.doi.org/10.1128/IAI.05182-11.
28. Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM. 2012. Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun 80:643-650. http://dx.doi.org/10.1128/IAI.05604-11.
29. Granoff DM, Bartoloni A, Ricci S, Gallo E, Rosa D, Ravenscroft N, Guarnieri V, Seid RC, Shan A, Usinger WR, Tan S, McHugh YE, Moe GR. 1998. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 160:5028-5036.
30. Moe GR, Zuno-Mitchell P, Lee SS, Lucas AH, Granoff DM. 2001. Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun 69:3762-3771. http://dx.doi.org/10.1128/IAI.69.6.3762-3771.2001.
31. Vu DM, Pajon R, Reason DC, Granoff DM. 2012. A broadly cross-reactive monoclonal antibody against an epitope on theNterminus of meningococcal FHbp. Sci Rep 2:341. http://dx.doi.org/10.1038/srep00341.
32. Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S. 2013. Factor H-dependent alternative pathway inhibition mediated by porinBcontributes to virulence of Neisseria meningitidis. mBio 4:e00339-13. http://dx.doi.org/10.1128/mBio.00339-13.
33. Vandeputte-Rutten L, Bos MP, Tommassen J, Gros P. 2003. Crystal structure of neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential. J Biol Chem 278:24825-24830. http://dx.doi.org/10.1074/jbc.M302803200.
34. Granoff DM, Welsch JA, Ram S. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77:764-769. http://dx.doi.org/10.1128/IAI.01191-08.
35. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, Quoraishi S, Lovett JE, Deane JE, Sim RB, Roversi P, Johnson S, Tang CM, Lea SM. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893. http://dx.doi.org/10.1038/nature07769.
36. Shaughnessy J, Vu DM, Punjabi R, Serra-Pladevall J, DeOliveira RB, Granoff DM, Ram S. 2014. Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic. Clin Vaccine Immunol 21:1452-1459. http://dx.doi.org/10.1128/CVI.00444-14.
37. Lewis LA, Vu DM, Granoff DM, Ram S. 2014. Inhibition of the alternative pathway of non-human infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect Immun 82:2574-2584. http://dx.doi.org/10.1128/IAI.01517-14.
38. Welsch JA, Ram S, Koeberling O, Granoff DM. 2008. Complementdependent synergistic bactericidal activity of antibodies against factor Hbinding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197:1053-1061. http://dx.doi.org/10.1086/528994.
39. Giuntini S, Reason DC, Granoff DM. 2012. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor H binding protein. Infect Immun 80:187-194. http://dx.doi.org/10.1128/IAI.05956-11.
40. Agarwal S, Vasudhev S, DeOliveira RB, Ram S. 2014. Inhibition of the classical pathway of complement by meningococcal capsular polysaccharides. J Immunol 193:1855-1863. http://dx.doi.org/10.4049/jimmunol.1303177.
41. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, Ngampasutadol J, Vogel U, Granoff DM, Ram S. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factorHand enhances serum resistance. J Immunol 177:501-510. http://dx.doi.org/10.4049/jimmunol.177.1.501.
42. Kattner C, Toussi DN, Zaucha J, Wetzler LM, Ruppel N, Zachariae U, Massari P, Tanabe M. 2014. Crystallographic analysis of Neisseria meningitidis PorB extracellular loops potentially implicated in TLR2 recognition. J Struct Biol 185:440-447. http://dx.doi.org/10.1016/j.jsb.2013.12.006.
43. Sanchez S, Arenas J, Abel A, Criado MT, Ferreiros CM. 2005. Analysis of outer membrane protein complexes and heat-modifiable proteins in Neisseria strains using two-dimensional diagonal electrophoresis. J Proteome Res 4:91-95. http://dx.doi.org/10.1021/pr049846i.
44. Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R, members of the Canadian Immunization Monitoring Program. 2013. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 32:124-130. http://dx.doi.org/10.1016/j.vaccine.2013.03.063.
45. Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. 2013. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine 31:1113-1116. http://dx.doi.org/10.1016/j.vaccine.2012.12.022.
46. Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, Comanducci M, Muzzi A, Taha MK. 2014. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol 14:111. http://dx.doi.org/10.1186/1471-2180-14-111.